Key Takeaways
- • Isomorphic Labs raised a $5 billion Series C round, its second multibillion-dollar financing in six months following a $2.1 billion Series B in May 2026.
- • Greenoaks and Sequoia Capital co-led the round, with participation from Andreessen Horowitz, several new investors, and Alphabet, Isomorphic's parent company.
- • All existing investors, including Thrive Capital, MGX, GV, CapitalG, Temasek and the U.K. Sovereign AI Fund, returned for the Series C.
- • Proceeds will fund development of the IsoDDE drug design engine, its preclinical pipeline in oncology and immunology, and translational and clinical infrastructure.
- • The company has not yet disclosed detailed preclinical data, and its drug candidates have not yet been tested in humans.
Summary
The Series C proceeds will fund further development of IsoDDE, the company's drug design engine, and the pipeline of preclinical programs it has generated. Isomorphic is also investing in translational and clinical development infrastructure to support moving programs into human testing. The internal pipeline spans multiple drug modalities and focuses on oncology and immunology, though the company has not yet provided program details. Isomorphic has said IsoDDE outperforms AlphaFold 3 on a protein-ligand structure prediction benchmark and identifies novel binding sites.
Isomorphic President Max Jaderberg, Ph.D., said in a statement that the company's machine learning researchers and drug hunters "are routinely solving complex biological problems that have stalled traditional research for decades." Fierce Biotech notes that the company has yet to show how IsoDDE-generated candidates perform in humans and has described its preclinical results only as "positive" without detailed data, leaving room for skepticism even as investors have committed large sums.
Greenoaks and Sequoia Capital co-led the Series C, with participation from Andreessen Horowitz and several other new investors. Alphabet made a significant investment. All existing investors, including Thrive Capital, MGX, GV, CapitalG, Temasek and the U.K. Sovereign AI Fund, returned for the round.
The round extends a track record of major announcements. In 2024, Isomorphic disclosed collaborations with Eli Lilly and Novartis with a combined value of about $3 billion, including milestones. The company raised $600 million in its first external funding round in 2025 and added Johnson & Johnson as a partner at the start of 2026.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.